Anticipating Clinical Integration of Pharmacogenetic Treatment Strategies for Addiction: Are Primary Care Physicians Ready?

Emerging pharmacogenomics research on addiction to nicotine,1 alcohol,2 cocaine, and opiates3 may soon lead to improved clinical outcomes by tailoring the type, dose and duration of treatment to individual patients’ genotypes. To realize the potential of pharmacogenomics in reducing the burden of ad...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2008-04, Vol.83 (4), p.635-639
Main Authors: Shields, AE, Lerman, C
Format: Article
Language:English
Subjects:
Clinical Competence
Genetic Predisposition to Disease
Genetic Research
Genetic Testing
Health Knowledge, Attitudes, Practice
Humans
Medically Underserved Area
Pharmacogenetics
Physicians, Family
Primary Health Care - organization & administration
Primary Health Care - standards
Primary Health Care - trends
Substance-Related Disorders - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4234-5a2c76388e2dbef6b14fd555062caf806dce3301895bb5cf0272dfbc8521cec93
cites cdi_FETCH-LOGICAL-c4234-5a2c76388e2dbef6b14fd555062caf806dce3301895bb5cf0272dfbc8521cec93
container_end_page 639
container_issue 4
container_start_page 635
container_title Clinical pharmacology and therapeutics
container_volume 83
creator Shields, AE
Lerman, C
description Emerging pharmacogenomics research on addiction to nicotine,1 alcohol,2 cocaine, and opiates3 may soon lead to improved clinical outcomes by tailoring the type, dose and duration of treatment to individual patients’ genotypes. To realize the potential of pharmacogenomics in reducing the burden of addiction, several challenges related to clinical integration of novel treatment strategies will need to be addressed concomitantly with ongoing empirical research.4 These challenges include the preparedness of primary care physicians (PCPs) to incorporate pharmacogenetics into clinical practice, patients’ willingness to undergo genetic testing, the resources and infrastructure needed to deliver such services, adequate financing and reimbursement of pharmacogenetic testing, and privacy and antidiscrimination protections sufficient to reassure physicians and patients that genetic testing will not lead to stigmatization and discrimination.4 Clinical Pharmacology & Therapeutics (2008); 83, 4, 635–639. doi:10.1038/clpt.2008.4
doi_str_mv 10.1038/clpt.2008.4
format article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1038_clpt_2008_4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CPTCLPT20084</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4234-5a2c76388e2dbef6b14fd555062caf806dce3301895bb5cf0272dfbc8521cec93</originalsourceid><addsrcrecordid>eNp9kN1LwzAUxYMobk6ffNe8S2eaNF3qi5Tix2Dg0Plc0vRmi7RpSTNk-M_bUtE3ny7n8jvnXg5ClyGZh4SJW1W1fk4JEfPoCE1DzmgQc8aP0ZQQkgQJZfEEnXXdRy-jRIhTNAkFo0zwZIq-UuuNMq30xm5xVhlrlKzw0nrYun7ZWNxovN5JV0vVbMFCj-ONA-lrsB6_-Z6CrYEO68bhtCyNGlx3OHWA187U0h1wJgexO3T9KWk7_AqyPNyfoxMtqw4ufuYMvT8-bLLnYPXytMzSVaAiyqKAS6oWMRMCaFmAjosw0iXnnMRUSS1IXCpgjIQi4UXBlSZ0QUtdKMFpqEAlbIZuxlzlmq5zoPN2_CsPST5UmA8V5kOFedTTVyPd7osayj_2p7Me4CPwaSo4_JeVZ-tNtlpvBjUEX48-K_3ewa9xMIzEN87fixY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Anticipating Clinical Integration of Pharmacogenetic Treatment Strategies for Addiction: Are Primary Care Physicians Ready?</title><source>Wiley</source><creator>Shields, AE ; Lerman, C</creator><creatorcontrib>Shields, AE ; Lerman, C</creatorcontrib><description>Emerging pharmacogenomics research on addiction to nicotine,1 alcohol,2 cocaine, and opiates3 may soon lead to improved clinical outcomes by tailoring the type, dose and duration of treatment to individual patients’ genotypes. To realize the potential of pharmacogenomics in reducing the burden of addiction, several challenges related to clinical integration of novel treatment strategies will need to be addressed concomitantly with ongoing empirical research.4 These challenges include the preparedness of primary care physicians (PCPs) to incorporate pharmacogenetics into clinical practice, patients’ willingness to undergo genetic testing, the resources and infrastructure needed to deliver such services, adequate financing and reimbursement of pharmacogenetic testing, and privacy and antidiscrimination protections sufficient to reassure physicians and patients that genetic testing will not lead to stigmatization and discrimination.4 Clinical Pharmacology &amp; Therapeutics (2008); 83, 4, 635–639. doi:10.1038/clpt.2008.4</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1038/clpt.2008.4</identifier><identifier>PMID: 18323859</identifier><language>eng</language><publisher>United States</publisher><subject>Clinical Competence ; Genetic Predisposition to Disease ; Genetic Research ; Genetic Testing ; Health Knowledge, Attitudes, Practice ; Humans ; Medically Underserved Area ; Pharmacogenetics ; Physicians, Family ; Primary Health Care - organization &amp; administration ; Primary Health Care - standards ; Primary Health Care - trends ; Substance-Related Disorders - genetics</subject><ispartof>Clinical pharmacology and therapeutics, 2008-04, Vol.83 (4), p.635-639</ispartof><rights>2008 American Society for Clinical Pharmacology and Therapeutics</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4234-5a2c76388e2dbef6b14fd555062caf806dce3301895bb5cf0272dfbc8521cec93</citedby><cites>FETCH-LOGICAL-c4234-5a2c76388e2dbef6b14fd555062caf806dce3301895bb5cf0272dfbc8521cec93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18323859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shields, AE</creatorcontrib><creatorcontrib>Lerman, C</creatorcontrib><title>Anticipating Clinical Integration of Pharmacogenetic Treatment Strategies for Addiction: Are Primary Care Physicians Ready?</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>Emerging pharmacogenomics research on addiction to nicotine,1 alcohol,2 cocaine, and opiates3 may soon lead to improved clinical outcomes by tailoring the type, dose and duration of treatment to individual patients’ genotypes. To realize the potential of pharmacogenomics in reducing the burden of addiction, several challenges related to clinical integration of novel treatment strategies will need to be addressed concomitantly with ongoing empirical research.4 These challenges include the preparedness of primary care physicians (PCPs) to incorporate pharmacogenetics into clinical practice, patients’ willingness to undergo genetic testing, the resources and infrastructure needed to deliver such services, adequate financing and reimbursement of pharmacogenetic testing, and privacy and antidiscrimination protections sufficient to reassure physicians and patients that genetic testing will not lead to stigmatization and discrimination.4 Clinical Pharmacology &amp; Therapeutics (2008); 83, 4, 635–639. doi:10.1038/clpt.2008.4</description><subject>Clinical Competence</subject><subject>Genetic Predisposition to Disease</subject><subject>Genetic Research</subject><subject>Genetic Testing</subject><subject>Health Knowledge, Attitudes, Practice</subject><subject>Humans</subject><subject>Medically Underserved Area</subject><subject>Pharmacogenetics</subject><subject>Physicians, Family</subject><subject>Primary Health Care - organization &amp; administration</subject><subject>Primary Health Care - standards</subject><subject>Primary Health Care - trends</subject><subject>Substance-Related Disorders - genetics</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp9kN1LwzAUxYMobk6ffNe8S2eaNF3qi5Tix2Dg0Plc0vRmi7RpSTNk-M_bUtE3ny7n8jvnXg5ClyGZh4SJW1W1fk4JEfPoCE1DzmgQc8aP0ZQQkgQJZfEEnXXdRy-jRIhTNAkFo0zwZIq-UuuNMq30xm5xVhlrlKzw0nrYun7ZWNxovN5JV0vVbMFCj-ONA-lrsB6_-Z6CrYEO68bhtCyNGlx3OHWA187U0h1wJgexO3T9KWk7_AqyPNyfoxMtqw4ufuYMvT8-bLLnYPXytMzSVaAiyqKAS6oWMRMCaFmAjosw0iXnnMRUSS1IXCpgjIQi4UXBlSZ0QUtdKMFpqEAlbIZuxlzlmq5zoPN2_CsPST5UmA8V5kOFedTTVyPd7osayj_2p7Me4CPwaSo4_JeVZ-tNtlpvBjUEX48-K_3ewa9xMIzEN87fixY</recordid><startdate>200804</startdate><enddate>200804</enddate><creator>Shields, AE</creator><creator>Lerman, C</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200804</creationdate><title>Anticipating Clinical Integration of Pharmacogenetic Treatment Strategies for Addiction: Are Primary Care Physicians Ready?</title><author>Shields, AE ; Lerman, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4234-5a2c76388e2dbef6b14fd555062caf806dce3301895bb5cf0272dfbc8521cec93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Clinical Competence</topic><topic>Genetic Predisposition to Disease</topic><topic>Genetic Research</topic><topic>Genetic Testing</topic><topic>Health Knowledge, Attitudes, Practice</topic><topic>Humans</topic><topic>Medically Underserved Area</topic><topic>Pharmacogenetics</topic><topic>Physicians, Family</topic><topic>Primary Health Care - organization &amp; administration</topic><topic>Primary Health Care - standards</topic><topic>Primary Health Care - trends</topic><topic>Substance-Related Disorders - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shields, AE</creatorcontrib><creatorcontrib>Lerman, C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shields, AE</au><au>Lerman, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anticipating Clinical Integration of Pharmacogenetic Treatment Strategies for Addiction: Are Primary Care Physicians Ready?</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2008-04</date><risdate>2008</risdate><volume>83</volume><issue>4</issue><spage>635</spage><epage>639</epage><pages>635-639</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><abstract>Emerging pharmacogenomics research on addiction to nicotine,1 alcohol,2 cocaine, and opiates3 may soon lead to improved clinical outcomes by tailoring the type, dose and duration of treatment to individual patients’ genotypes. To realize the potential of pharmacogenomics in reducing the burden of addiction, several challenges related to clinical integration of novel treatment strategies will need to be addressed concomitantly with ongoing empirical research.4 These challenges include the preparedness of primary care physicians (PCPs) to incorporate pharmacogenetics into clinical practice, patients’ willingness to undergo genetic testing, the resources and infrastructure needed to deliver such services, adequate financing and reimbursement of pharmacogenetic testing, and privacy and antidiscrimination protections sufficient to reassure physicians and patients that genetic testing will not lead to stigmatization and discrimination.4 Clinical Pharmacology &amp; Therapeutics (2008); 83, 4, 635–639. doi:10.1038/clpt.2008.4</abstract><cop>United States</cop><pmid>18323859</pmid><doi>10.1038/clpt.2008.4</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0009-9236
ispartof Clinical pharmacology and therapeutics, 2008-04, Vol.83 (4), p.635-639
issn 0009-9236
1532-6535
language eng
recordid cdi_crossref_primary_10_1038_clpt_2008_4
source Wiley
subjects Clinical Competence
Genetic Predisposition to Disease
Genetic Research
Genetic Testing
Health Knowledge, Attitudes, Practice
Humans
Medically Underserved Area
Pharmacogenetics
Physicians, Family
Primary Health Care - organization & administration
Primary Health Care - standards
Primary Health Care - trends
Substance-Related Disorders - genetics
title Anticipating Clinical Integration of Pharmacogenetic Treatment Strategies for Addiction: Are Primary Care Physicians Ready?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T23%3A44%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anticipating%20Clinical%20Integration%20of%20Pharmacogenetic%20Treatment%20Strategies%20for%20Addiction:%20Are%20Primary%20Care%20Physicians%20Ready?&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Shields,%20AE&rft.date=2008-04&rft.volume=83&rft.issue=4&rft.spage=635&rft.epage=639&rft.pages=635-639&rft.issn=0009-9236&rft.eissn=1532-6535&rft_id=info:doi/10.1038/clpt.2008.4&rft_dat=%3Cwiley_cross%3ECPTCLPT20084%3C/wiley_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4234-5a2c76388e2dbef6b14fd555062caf806dce3301895bb5cf0272dfbc8521cec93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/18323859&rfr_iscdi=true